Acetyl-Carnitine and Reduced Ammonium Level

Safety in these studies

non-serious adverse eventsIncreased riskRR 2.51, 95% CI 0.68 to 9.22
It is unclear whether acetyl-L-carnitine versus placebo increases the risk of non-serious adverse events (8/126 (6.34%) vs 3/120 (2.50%); RR 2.51, 95% CI 0.68 to 9.22; 2 trials; very low-quality evidence).
from: Acetyl-L-carnitine for patients with hepatic encephalopathy.
Overall tolerabilityReported
Overall, adverse events data were poorly reported and harms may have been underestimated.
from: Acetyl-L-carnitine for patients with hepatic encephalopathy.

1 of 1 paper

Acetyl-L-carnitine for patients with hepatic encephalopathy.